Global Single-Cell Multi-Omics Market - GLOBAL:2021

Market Report Coverage :
Start Year : 2020 - Forecast Year : 2025 - Start Value : $1,221.5 Million in 2020 - Forecast Value : $3,188.9 Million by 2025 - CAGR % : 0.21%
Description :
Market Report Coverage - Single-Cell Multi-OmicsMarket Segmentation• Product Type – Consumables, Instruments, and Software• Sample Type – Human Samples, Animal Samples, and Microbial Samples• Omics Type – Single-Cell Transcriptomics, Single-Cell Genomics, Single-Cell Proteomics• Application – Clinical Research, Translational Research, and Synthetic Biology• Technique – Single-Cell Isolation and Dispensing and Single-Cell Analysis• End User – Academic and Research Institutions, Biopharmaceutical and Biotechnological Companies, Contract Research Organizations, and Other End UsersRegional Segmentation• North America – U.S., Canada• Europe – Germany, France, Italy, U.K., Spain, and Rest-of-Europe• Asia-Pacific – China, Japan, India, Singapore, Australia, and Rest-of-Asia-Pacific (RoAPAC)• Latin America – Brazil, Mexico, and Rest-of-the-Latin America• Rest-of-the-WorldGrowth Drivers• Increasing number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (sc-RNA)• Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders• Increasing Disposable Income in Emerging EconomiesMarket Restraints• High Cost of Single-Cell Analysis and Integration of Data• Limited Availability of Large Online Data Storage and Analysis PlatformsMarket Opportunities• Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations• Requirement for the Development of Advanced Solutions Based on Single-Cell Technology• Increased Use of Single-Cell Technology Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan• Expansion into New Research Application such as Single-Cell MetabolomicsKey Companies Profiled1CellBio, Inc., Fluidigm Corporation, 10x Genomics, Inc., NanoString Technologies, Inc., Bio-Techne Corporation, Bio-Rad Laboratories, Inc., Mission Bio, Dolomite Bio, Fluxion Biosciences, Berkeley Lights, Inc., RareCyte, Inc., Becton, Dickinson and Company, Takara Bio, Inc., Thermo Fisher Scientific Inc., Namocell, Inc.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global single-cell multi-omics market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global single-cell multi-omics market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on the following segments: o product type o omics type o technique o sample type o application o end user o region, namely North America, Europe, Asia-Pacific, Rest-of-the-World (RoW) • Which are the leading players with significant offerings to the global single-cell multi-omics market? What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global single-cell multi-omics market?Market OverviewBIS Research healthcare experts have found the single-cell multi-omics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 21.16% during the forecast period, 2020-2025. The market is driven by the need for the development of an advanced solution based on single-cell technology for clinical research in various applications such as cancer, rare disease, cell biology, and synthetic biology, among others.The market is favored by the development of single-cell technology-based solutions for visualization and analysis of cell heterogeneity, tumor microenvironment, and antibody development. The gradual increase in the prevalence of oncology and rare diseases globally has furthered the single-cell multi-omics market.Furthermore, several contract research organizations are focusing on the development of single-cell technology-based services, which enable simultaneous analysis of genomics, proteomics, and transcriptomics, providing deeper insights on a disease progression.Within the research report, the market is segmented on the basis of product type, sample type, omics type, technique, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.Competitive LandscapeThe exponential rise in the application of precision medicine on the global level has created a buzz among companies to invest in the development of high-resolution multiplex diagnostics providing information on cellular interaction and tissue heterogeneity to understand disease biology and pathology. Due to technologically advanced solutions and intense market penetration, 10x Genomics, Inc. has been a pioneer and a significant competitor in this market.Other key players in the market are NanoString Technologies, Inc., RareCyte, Inc., Fluidigm Corporation, Becton, Dickinson and Company, Thermo Fisher Sciences, Fluxion Biosciences, Bio-Rad Laboratories, Inc., Namocell, Inc., 1Cell Bio, Inc., Mission Bio, Berkeley Lights, Takara Bio, Inc., Dolomite Bio, and Bio-Techne Corporation.On the basis of region, North America holds the largest share of the single-cell multi-omics market due to improved healthcare infrastructure, rise in per capita income, and availability of state-of-the-art research laboratories and institutions in the region. Apart from this, Asia-Pacific is anticipated to grow at the fastest CAGR of 21.53% during the forecast period 2020-2025.The market utilizes several technologies, such as barcoding, sequencing, mass cytometry, and microscopy, for the development of instruments and assays for single-cell analysis of tissue and cells to gain an understanding of cell heterogeneity and cellular mechanism. Each solution offered by the leading players is the combination of next-generation omics tools for application in several clinical areas, such as oncology, neurology, immunology, and pathology.
Countries Covered :
North America U.S. CanadaEurope Germany Italy France Spain U.K. Rest-of-EuropeAsia-Pacific China India Australia Singapore Japan Rest-of-Asia-PacificLatin America Brazil Mexico Rest-of-Latin AmericaRest-of-the-Word
Keywords :
Single Cell Multi Omics, Multi Omics, Single Cell Sequencing, Single Cell Multi Omics Market, Single Cell Multi Omics Report, Single Cell Multi Omics Industry, Single Cell Multi Omics Market Forecast, Single Cell Multi Omics Trends, Single Cell Multi Omics Products, Single Cell Multi Omics Applications, Single Cell Multi Omics Technology, Single Cell Multi Omics Companies, Single Cell Multi Omics Market Analysis, Single Cell Multi Omics Industry Analysis, What is Single Cell Multi Omics Market, What are Single Cell Multi Omics Market, Single Cell Multi Omics Market by Product Type, Single Cell Multi Omics Market by Omics Type, Single Cell Multi Omics Market by Sample Type, Single Cell Multi Omics Market by Technique, Single Cell Multi Omics Market by Application, Single Cell Multi Omics Market by End User, Single Cell Multi Omics Market by Region, Europe Single Cell Multi Omics Market, Asia-Pacific Single Cell Multi Omics Market, Latin America Single Cell Multi Omics Market
Press Release :
NGS has fundamentally changed genomics research and gained the attention of many biopharmaceutical companies and research institutions across a variety of applications, such as clinical diagnostics, drug discovery and development, forensics, and consumer genomics. Next-generation sequencing provides the backbone for single-cell library preparation in order to further this technology for the development of personalized medicine. It is estimated that the cost of sequencing under the Human Genome Project was $3 billion. Ten years ago, the cost of sequencing plummeted to $200,000, compared with the current cost of $600 (BGI, China).Progress in the sequencing fields has paved the way for the development of massively parallel, high-throughput sequencing technologies, known as single-cell RNA sequencing and whole-genome sequencing. Compared to Sanger sequencing, whole-genome and exome sequencing technologies allow sequencing of billions of fragments in one-run while decreasing the cost per run and time. To date, progress in whole-genome and exome sequencing technologies has reduced the cost of sequencing from $10 million to approximately $1,000, and further evolution of this technology is aimed at decreasing the cost of sequencing to $100.Further, Innovative Medicines Initiative (IMI), a strategic research agenda by the European Union with a budget of approximately $3.6 billion, is encouraging collaborations between universities, pharmaceutical and diagnostic companies, SMEs, patient organizations, regulatory bodies, and payers by financing major research projects for the development of biomarkers, companion diagnostics, and sequencing-based genetic tests.As per BIS Research analysis, the global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.Companies Mentioned in the Report:• 1CellBio, Inc.• Fluidigm Corporation• 10x Genomics, Inc.• NanoString Technologies, Inc.• Bio-Techne Corporation• Bio-Rad Laboratories, Inc.• Mission Bio• Dolomite Bio• Fluxion Biosciences• Berkeley Lights, Inc.• RareCyte, Inc.• Becton, Dickinson and Company• Takara Bio, Inc.• Thermo Fisher Scientific Inc.• Namocell, Inc.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global single-cell multi-omics market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global single-cell multi-omics market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on the following segments: o product type o omics type o technique o sample type o application o end user o region, namely North America, Europe, Asia-Pacific, Rest-of-the-World (RoW) • Which are the leading players with significant offerings to the global single-cell multi-omics market? What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global single-cell multi-omics market?
Companies Mentioned :
1CellBio, Inc.Fluidigm Corporation10x Genomics, Inc.NanoString Technologies, Inc.Bio-Techne CorporationBio-Rad Laboratories, Inc.Mission BioDolomite BioFluxion BiosciencesBerkeley Lights, Inc.RareCyte, Inc.Becton, Dickinson and CompanyTakara Bio, Inc.Thermo Fisher Scientific Inc.Namocell, Inc.
Press Release :
NGS has fundamentally changed genomics research and gained the attention of many biopharmaceutical companies and research institutions across a variety of applications, such as clinical diagnostics, drug discovery and development, forensics, and consumer genomics. Next-generation sequencing provides the backbone for single-cell library preparation in order to further this technology for the development of personalized medicine. It is estimated that the cost of sequencing under the Human Genome Project was $3 billion. Ten years ago, the cost of sequencing plummeted to $200,000, compared with the current cost of $600 (BGI, China).Progress in the sequencing fields has paved the way for the development of massively parallel, high-throughput sequencing technologies, known as single-cell RNA sequencing and whole-genome sequencing. Compared to Sanger sequencing, whole-genome and exome sequencing technologies allow sequencing of billions of fragments in one-run while decreasing the cost per run and time. To date, progress in whole-genome and exome sequencing technologies has reduced the cost of sequencing from $10 million to approximately $1,000, and further evolution of this technology is aimed at decreasing the cost of sequencing to $100.Further, Innovative Medicines Initiative (IMI), a strategic research agenda by the European Union with a budget of approximately $3.6 billion, is encouraging collaborations between universities, pharmaceutical and diagnostic companies, SMEs, patient organizations, regulatory bodies, and payers by financing major research projects for the development of biomarkers, companion diagnostics, and sequencing-based genetic tests.As per BIS Research analysis, the global single-cell multi-omics market is projected to reach $3,188.9 million by 2025 from $1,221.5 million in 2020, at a CAGR of 21.16% during the forecast period, 2020-2025.Companies Mentioned in the Report:• 1CellBio, Inc.• Fluidigm Corporation• 10x Genomics, Inc.• NanoString Technologies, Inc.• Bio-Techne Corporation• Bio-Rad Laboratories, Inc.• Mission Bio• Dolomite Bio• Fluxion Biosciences• Berkeley Lights, Inc.• RareCyte, Inc.• Becton, Dickinson and Company• Takara Bio, Inc.• Thermo Fisher Scientific Inc.• Namocell, Inc.Key Questions Answered in this Report:• What are the major market drivers, challenges, and opportunities in the global single-cell multi-omics market?• What is the potential impact of biotechnological advancements in the diagnostic industry among end users such as researchers, pathologists, and laboratory technicians?• What is the current market demand along with future expected demand for the global single-cell multi-omics market?• What are the key development strategies that are implemented by the major players in order to sustain the competitive market? • How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on the following segments: o product type o omics type o technique o sample type o application o end user o region, namely North America, Europe, Asia-Pacific, Rest-of-the-World (RoW) • Which are the leading players with significant offerings to the global single-cell multi-omics market? What is the expected market dominance for each of these leading players? • Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global single-cell multi-omics market?
Headline :
Global Single-Cell Multi-Omics Market to Reach $3,188.9 Million by 2025
Table of Contents :
Executive Summary 1 Product Definition1.1 Inclusion and Exclusion2 Scope of Work2.1 Scope of the Study2.2 Key Questions Addressed in the Report3 Research Methodology3.1 Primary Data Sources3.2 Secondary Data Sources3.3 Market Estimation Model3.4 Criteria for Company Profiling4 Market Overview4.1 Introduction4.1.1 Technological Development in Single-Cell Sequencing4.1.1.1 Advancements in Imaging Techniques for Single-Cell Sequencing4.1.1.2 Advancements in Single-Cell Collection and Analysis System5 Market Dynamics5.1 Overview5.2 Impact Analysis5.3 Market Drivers5.3.1 Increasing number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (sc-RNA)5.3.2 Increasing Adoption of Personalized Medicine for the Screening and Diagnostics of Genetic Disorders5.3.3 Increasing Disposable Income in Emerging Economies5.4 Market Restraints5.4.1 High Cost of Single-Cell Analysis and Integration of Data5.4.2 Limited Availability of Large Online Data Storage and Analysis Platforms5.5 Market Opportunities5.5.1 Massive Scope for Adoption of Genomic-Based Medicine in Emerging Nations5.5.2 Requirement for the Development of Advanced Solutions Based on Single-Cell Technology5.5.3 Increased Use of Single-Cell Technology Solutions for the Development of Therapeutics Drugs and Comprehensive Treatment Plan5.5.4 Expansion into New Research Applications such as Single-Cell Metabolomics6 Competitive Insights6.1 Market Share Analysis (by Company), 20196.2 Growth Share Analysis (Opportunity Mapping)6.2.1 By Company7 Global Single-Cell Multi-Omics Market (by Product Type)7.1 Instruments7.2 Consumables7.3 Software8 Global Single-Cell Multi-Omics Market (by Omics Type)8.1 Single-Cell Genomics8.2 Single-Cell Transcriptomics8.3 Single-Cell Proteomics9 Global Single-Cell Multi-Omics Market (by Sample Type)9.1 Human Samples9.1.1 Cancer Tissues9.1.2 Stem Cells9.1.3 Brain Cells9.1.4 Immune Cells9.1.5 Other Samples9.2 Animal Samples9.3 Microbial Samples10 Global Single-Cell Multi-Omics Market (by Technique)10.1 Single-Cell Isolation and Dispensing10.1.1 Fluorescence-Activated Cell Sorting (FACS)10.1.2 Manual Cell Picking10.1.3 Magnetic-Activated Cell Sorting (MACS)10.1.4 Laser Capture Microdissection10.1.5 Random Seeding10.1.6 Microfluidics10.1.7 Others10.2 Single-Cell Analysis10.2.1 Mass Cytometry10.2.2 Polymerase Chain Reaction10.2.3 Next-Generation Sequencing10.2.4 Mass Spectrometry10.2.5 Others11 Global Single-Cell Multi-Omics Market (by Application)11.1 Clinical Research11.1.1 Oncology11.1.2 Immunology11.1.3 Neurology11.1.4 Cell Therapy11.1.5 Cell Biology11.1.6 Others11.2 Translation Research11.3 Synthetic Biology12 Global Single-Cell Multi-Omics Market (by End User)12.1 Overview12.2 Research and Academic Laboratories12.3 Contract Research Organizations12.4 Biopharmaceutical and Biotech Companies12.5 Others End Users13 Global Single-Cell Multi-Omics Market (by Region)13.1 Overview13.1.1 U.S.13.1.2 Canada13.2 Europe13.2.1 Germany13.2.2 France13.2.3 U.K.13.2.4 Italy13.2.5 Spain13.2.6 Rest-of-Europe13.3 Asia-Pacific13.3.1 Japan13.3.2 Singapore13.3.3 India13.3.4 China13.3.5 Australia13.3.6 Rest-of-APAC13.4 Latin America13.4.1 Mexico13.4.2 Brazil13.4.3 Rest-of-Latin America13.5 Rest-of-the-World14 Company Profiles14.1 Overview14.2 1CellBio, Inc.14.2.1 Company Overview14.2.2 Role of 1CellBio, Inc. in the Global Single-Cell Multi-Omics Market14.2.3 SWOT Analysis14.3 Fluidigm Corporation14.3.1 Company Overview14.3.2 Role of Fluidigm Corporation in Global Single-Cell Multi-Omics Market14.3.3 Financials14.3.4 Key Insights About Financial Health of the Company14.3.5 SWOT Analysis14.4 10x Genomics, Inc.14.4.1 Company Overview14.4.2 Role of 10x Genomics, Inc. in Global Single-Cell Multi-Omics Market14.4.3 Financials14.4.4 Key Insights About Financial Health of the Company14.4.5 SWOT Analysis14.5 NanoString Technologies, Inc.14.5.1 Company Overview14.5.2 Role of NanoString Technologies, Inc. in Global Single-Cell Multi-Omics Market14.5.3 Key Insights About Financial Health of the Company14.5.4 SWOT Analysis14.6 Bio-Techne Corporation14.6.1 Company Overview14.6.2 Role of Bio-Techne Corporation in Global Single-Cell Multi-Omics Market14.6.3 Key Insights About Financial Health of the Company14.6.4 SWOT Analysis14.7 Bio-Rad Laboratories, Inc.14.7.1 Company Overview14.7.2 Role of Bio-Rad Laboratories, Inc. in Global Single-Cell Multi-Omics Market14.7.3 Financials14.7.4 Key Insights About Financial Health of the Company14.7.5 SWOT Analysis14.8 Mission Bio14.8.1 Company Overview14.8.2 Role of Mission Bio in the Single-Cell Multi-Omics Market14.8.3 SWOT Analysis14.9 Dolomite Bio14.9.1 Company Overview14.9.2 Role of Dolomite Bio in the Single-Cell Multi-Omics Market14.9.3 SWOT Analysis14.1 Fluxion Biosciences14.10.1 Company Overview14.10.2 Role of Fluxion Biosciences in the Global Single-Cell Multi-Omics Market14.10.3 SWOT Analysis14.11 Berkeley Lights, Inc.14.11.1 Company Overview14.11.2 Role of Berkeley Lights, Inc. in Global Single-Cell Multi-Omics Market14.11.3 Financials14.11.4 Key Insights About Financial Health of the Company14.11.5 SWOT Analysis14.12 RareCyte, Inc.14.12.1 Company Overview14.12.2 Role of RareCyte, Inc. in Global Single-Cell Multi-Omics Market14.12.3 SWOT Analysis14.13 Becton, Dickinson and Company14.13.1 Company Overview14.13.2 Role of Becton, Dickinson and Company in the Global Single-Cell Multi-Omics Market14.13.3 Key Insights About Financial Health of the Company14.13.4 SWOT Analysis14.14 Takara Bio, Inc.14.14.1 Company Overview14.14.2 Role of Takara Bio, Inc. in the Global Single-Cell Multi-Omics Market14.14.3 Key Insights About Financial Health of Company14.14.4 SWOT Analysis14.15 Thermo Fisher Scientific Inc.14.15.1 Company Overview14.15.2 Role of Thermo Fisher Scientific Inc. in Global Single-Cell Multi-Omics Market14.15.3 Financials14.15.4 Key Insights About Financial Health of the Company14.15.5 SWOT Analysis14.16 Namocell, Inc.14.16.1 Company Overview14.16.2 Role of Namocell, Inc. in the Single-Cell Multi-Omics Market14.16.3 SWOT Analysis15 Emerging Companies15.1 Proteona15.1.1 Company Overview15.1.2 Role of Proteona in the Single-Cell Multi-Omics Market15.2 BioTuring, Inc.15.2.1 Company Overview15.2.2 Role of BioTuring, Inc. in the Single-Cell Multi-Omics Market15.3 Scipio Biosciences SAS15.3.1 Company Overview15.3.2 Role of Scipio Biosciences SAS in the Single-Cell Multi-Omics Market15.4 Parse Biosciences, Inc.15.4.1 Company Overview15.4.2 Role of Parse Biosciences, Inc. in the Single-Cell Multi-Omics Market15.5 Shilps Sciences15.5.1 Company Overview15.5.2 Role of Shilps Sciences in the Single-Cell Multi-Omics MarketList of Tables Table 1: Per Sample Clinical Cost of WGS and WESTable 5.1: Likert ScaleTable 5.2: Impact Analysis of Market DriversTable 5.3: Impact Analysis of Market RestraintsTable 5.4: Per Sample Clinical Cost of WGS and WESTable 7.1: Single-Cell Multi-Omics Market (Instruments)Table 7.2: Single-Cell Multi-Omics Market (Consumables)Table 7.3: Single-Cell Multi-Omics Market (Software)Table 10.1: Products for Fluorescence-Activated Cell SortingTable 10.2: Products for Manual Cell PickingTable 10.3: Products for Magnetic-Activated Cell SortingTable 10.4: Products for Laser MicrodissectionTable 10.5: Products for Random Seeding/Limited DilutionTable 10.6: Products for MicrofluidicsList of Figures Figure 1: Impact Analysis of Market Drivers and Market Challenges on Global Single-Cell Multi-Omics MarketFigure 2: Global Single-Cell Multi-Omics Market (by Product Type), $Million, 2020 vs. 2025Figure 3: Global Single-Cell Multi-Omics Market (by Application), $Million, 2020 vs. 2025Figure 4: Global Single-Cell Multi-Omics Market (by Omics Type), $Million, 2020 vs. 2025Figure 5: Global Single-Cell Multi-Omics Market (by Technique), $Million, 2020 vs. 2025Figure 6: Global Single-Cell Multi-Omics Market (by Sample Type), $Million, 2020 vs. 2025Figure 7: Global Single-Cell Multi-Omics Market (by End User), $Million, 2020 vs. 2025Figure 8: Global Single-Cell Multi-Omics Market SnapshotFigure 3.1: Primary Research MethodologyFigure 3.2: Bottom-Up Approach (Segment-Wise Analysis)Figure 3.3: Top-Down Approach (Segment-Wise Analysis)Figure 4.1: Single-Cell Multi-Omics ApproachFigure 4.2: Evolution of Single-Cell Multi-Omics TechnologyFigure 4.4: Three Major Technological Developments in Single-Cell SequencingFigure 4.5: Traditional and Modern Approaches for Single-Cell IsolationFigure 5.1: U.S. Prevalence of Lyme Disease 2009-2018Figure 5.2: Global Prevalence Rate of Selected Rare Diseases Per 100,000 PeopleFigure 6.1: Market Share Analysis for the Global Single-Cell Multi-Omics Market, 2019Figure 6.2: Growth Share Matrix for Global Single-Cell Multi-Omics Market (by Company), 2019Figure 7.1: Global Single-Cell Multi-Omics Market (by Product Type)Figure 7.2: Global Single-Cell Multi-Omics Market (Instruments), 2019-2025Figure 7.3: Global Single-Cell Multi-Omics (Consumables), $Million, 2019-2025Figure 7.4: Global Single-Cell Multi-Omics Market (Software), $Million, 2019-2025Figure 8.1: Types of Omics PlatformsFigure 8.2: Global Single-Cell Genomics Market, $Million, 2019-2025Figure 8.3: Global Single-Cell Transcriptomics Market, $Million, 2019-2025Figure 8.4: Global Single-Cell Proteomics Market, $Million, 2019-2025Figure 9.1: Global Single-Cell Multi-Omics Market (by Sample Type), $Million, 2019-2025Figure 9.2: Global Single-Cell Multi-Omics Market (Human Samples), $Million, 2019-2025Figure 9.3: Global Single-Cell Multi-Omics Market (Cancer Tissue), $Million, 2019-2025Figure 9.4: Global Single-Cell Multi-Omics Market (Stem Cells), $Million, 2019-2025Figure 9.5: Global Single-Cell Multi-Omics Market (Brain Cells), $Million, 2019-2025Figure 9.6: Global Single-Cell Multi-Omics Market (Immune Cells), $Million, 2019-2025Figure 9.7: Global Single-Cell Multi-Omics Market (Other Samples), $Million, 2019-2025Figure 9.8: Global Single-Cell Multi-Omics Market (Animal Samples), $Million, 2019-2025Figure 9.9: Global Single-Cell Multi-Omics Market (Microbial Samples), $Million, 2019-2025Figure 10.1: Global Single-Cell Multi-Omics Market (by Technique)Figure 10.2: Global Single-Cell Multi-Omics (Single-Cell Isolation and Dispensing), $Million, 2019-2025Figure 10.3: Global Single-Cell Multi-Omics Market (FACS), $Million, 2019-2025Figure 10.4: Global Single-Cell Multi-Omics Market (Manual Cell Picking), $Million, 2019-2025Figure 10.5: Global Single-Cell Multi-Omics Market (MACS), $Million, 2019-2025Figure 10.6: Global Single-Cell Multi-Omics Market (LCM), $Million, 2019-2025Figure 10.7: Global Single-Cell Multi-Omics Market (Random Seeding), $Million, 2019-2025Figure 10.8: Global Single-Cell Multi-Omics Market (Microfluidics), $Million, 2019-2025Figure 10.9: Global Single-Cell Multi-Omics Market (Others), $Million, 2019-2025Figure 10.10: Global Single-Cell Multi-Omics (Single-Cell Analysis), $Million, 2019-2025Figure 10.11: Global Single-Cell Multi-Omics Market (Mass Cytometry), $Million, 2019-2025Figure 10.12: Global Single-Cell Multi-Omics Market (Polymerase Chain Reaction), $Million, 2019-2025Figure 10.13: Global Single-Cell Multi-Omics Market (Next-Generation Sequencing), $Million, 2019-2025Figure 10.14: Global Single-Cell Multi-Omics Market (Mass Spectrometry), $Million, 2019-2025Figure 10.15: Global Single-Cell Multi-Omics Market (Others), $Million, 2019-2025Figure 11.1: Global Single-Cell Multi-Omics Market (Clinical Research), $Million, 2019-2025Figure 11.2: Global Single-Cell Multi-Omics Market (Oncology), $Million, 2019-2025Figure 11.3: Global Single-Cell Multi-Omics Market (Immunology), $Million, 2019-2025Figure 11.4: Global Single-Cell Multi-Omics Market (by Neurology), $Million, 2019-2025Figure 11.5: Global Single-Cell Multi-Omics Market (Cell Therapy), $Million, 2019-2025Figure 11.6: Global Single-Cell Multi-Omics Market (Cell Biology), $Million, 2019-2025Figure 11.7: Global Single-Cell Multi-Omics Market (Others), $Million, 2019-2025Figure 11.8: Global Single-Cell Multi-Omics Market (Translational Research), $Million, 2019-2025Figure 11.9: Global Single-Cell Multi-Omics Market (Synthetic Biology), $Million, 2019-2025Figure 12.1: Global Single-Cell Multi-Omics Market (Research and Academia), $Million, 2019-2025Figure 12.2: Global Single-Cell Multi-Omics Market (Contract Research Organizations), $Million, 2019-2025Figure 12.3: Global Single-Cell Multi-Omics Market (Biopharmaceutical and Biotech Companies), $Million, 2019-2025Figure 12.4: Global Single-Cell Multi-Omics Market (Other End Users), $Million, 2019-2025Figure 13.1: Global Single-Cell Multi-Omics Market (by Region), $Million, 2020 and 2025Figure 13.2: Global Single-Cell Multi-Omics Market (by Region), $Million, 2019-2025Figure 13.3: North America Global Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.4: North America: Market DynamicsFigure 13.5: North America Single-Cell Multi-Omics Market (by Country), $Million, 2019-2025Figure 13.6: U.S. Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.7: Canada Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.8: Europe Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.9: Europe: Market DynamicsFigure 13.10: Europe Global Single-Cell Multi-Omics Market (by Country), $Million, 2019-2025Figure 13.11: Germany Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.12: France Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.13: U.K. Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.14: Italy Single-Cell Multi-Omics Market, $Millions, 2019-2025Figure 13.15: Spain Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.16: Rest-of-Europe Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.17: Asia-Pacific Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.18: APAC: Market DynamicsFigure 13.19: APAC Single-Cell Multi-Omics Market (by Country), $Million, 2019-2025Figure 13.20: Japan Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.21: Singapore Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.22: India Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.23: China Single-Cell Multi-Omics Market, 2019-2025Figure 13.24: Australia Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.25: RoAPAC Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.26: Latin America Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.27: Latin America: Market DynamicsFigure 13.28: Latin America Single-Cell Multi-Omics Market (by Country), 2019-2025Figure 13.29: Mexico Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.30: Brazil Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.31: Rest-of-Latin America Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 13.32: RoW Single-Cell Multi-Omics Market, $Million, 2019-2025Figure 14.1: Total Number of Companies ProfiledFigure 14.2: 1CellBio, Inc.: Product PortfolioFigure 14.3: 1CellBio: SWOT AnalysisFigure 14.4: Fluidigm Corporation: Product PortfolioFigure 14.5: Fluidigm Corporation: Overall Financials, 2017-2019Figure 14.6: Fluidigm Corporation: Revenue (by Business Segment), 2017-2019Figure 14.7: Fluidigm Corporation.: Revenue (by Region), 2017-2019Figure 14.8: Fluidigm Corporation: R&D Expenditure, 2017-2019Figure 14.9: Fluidigm Corporation: SWOT AnalysisFigure 14.10: 10x Genomics, Inc.: Product PortfolioFigure 14.11: 10x Genomics, Inc.: Overall Financials, 2017-2019Figure 14.12: 10x Genomics, Inc.: Revenue (by Business Segment), 2017-2019Figure 14.13: 10x Genomics, Inc.: Revenue (by Region), 2017-2019Figure 14.14: 10x Genomics, Inc.: R&D Expenditure, 2017-2019Figure 14.15: 10x Genomics, Inc.: SWOT AnalysisFigure 14.16: NanoString Technologies, Inc.: Product PortfolioFigure 14.17: NanoString Technologies, Inc.: Overall Financials, 2017-2019Figure 14.18: NanoString Technologies, Inc.: Revenue (by Business Segment), 2017-2019Figure 14.19: NanoString Technologies, Inc.: Revenue (by Region), 2017-2019Figure 14.20: NanoString Technologies, Inc.: R&D Expenditure, 2017-2019Figure 14.21: NanoString Technologies, Inc.: SWOT AnalysisFigure 14.22: Bio-Techne Corporation: Product PortfolioFigure 14.23: Bio-Techne Corporation: Overall Financials, 2020-2020Figure 14.24: Bio-Techne Corporation: Revenue (by Business Segment), 2020-2020Figure 14.25: Bio-Techne Corporation: Revenue (by Region), 2020-2020Figure 14.26: Bio-Techne Corporation: R&D Expenditure, 2020-2020Figure 14.27: Bio-Techne Corporation: SWOT AnalysisFigure 14.28: Bio-Rad Laboratories, Inc.: Product PortfolioFigure 14.29: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019Figure 14.30: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019Figure 14.31: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019Figure 14.32: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019Figure 14.33: Bio-Rad Laboratories, Inc.: SWOT AnalysisFigure 14.34: Mission Bio: Product PortfolioFigure 14.35: Mission Bio: SWOT AnalysisFigure 14.36: Dolomite Bio: Product PortfolioFigure 14.37: Dolomite Bio: SWOT AnalysisFigure 14.38: Fluxion Biosciences, Inc.: Product PortfolioFigure 14.39: Fluxion Biosciences, Inc.: SWOT AnalysisFigure 14.40: Berkeley Lights, Inc.: Product PortfolioFigure 14.41: Berkeley Lights, Inc.: Overall Financials, 2019-2020Figure 14.42: Berkeley Lights, Inc.: Revenue (by Segment), 2018-2019Figure 14.43: Berkeley Lights, Inc.: R&D Expenditure, 2017-2019Figure 14.44: Berkeley Lights, Inc.: SWOT AnalysisFigure 14.45: RareCyte, Inc.: Overall Product PortfolioFigure 14.46: RareCyte, Inc.: SWOT AnalysisFigure 14.47: Becton, Dickinson and Company: Product PortfolioFigure 14.48: Becton, Dickinson and Company: Overall Financials, 2020-2020Figure 14.49: Becton, Dickinson and Company: Revenue (by Business Segment), 2018-2020Figure 14.50: Becton, Dickinson and Company: Revenue (by Region), 2018-2020Figure 14.51: Becton, Dickinson and Company: R&D Expenditure, $Million, 2018-2020Figure 14.52: Becton, Dickinson and Company: SWOT AnalysisFigure 14.53: Takara Bio, Inc.: Product PortfolioFigure 14.54: Takara Bio Inc.: Overall Financials, (2018-2020)Figure 14.55: Takara Bio, Inc.: Revenue (by Business Segment), 2018-2020Figure 14.56: Takara Bio, Inc.: Revenue (by Region), 2019-2020Figure 14.57: Takara Bio, Inc., R&D Expenditure, 2018-2020Figure 14.58: Takara Bio Inc.: SWOT AnalysisFigure 14.59: Thermo Fisher Scientific, Inc.: Product PortfolioFigure 14.60: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019Figure 14.61: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), 2017-2019Figure 14.62: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019Figure 14.63: Thermo Fisher Scientific Inc.: R&D Expenditure (2017-2019)Figure 14.64: Thermo Fisher Scientific Inc.: SWOT AnalysisFigure 14.65: Namocell, Inc.: Product PortfolioFigure 14.66: Namocell, Inc.: SWOT AnalysisFigure 15.1: Proteona: Product PortfolioFigure 15.2: BioTuring, Inc.: Product PortfolioFigure 15.3: Parse Biosciences, Inc.: Product PortfolioFigure 15.4: Shilps Sciences: Product Portfolio